June 26, 2025 — Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]
June 24, 2025 — On the closing day of the ADA Scientific Sessions in Chicago, we got a good look at two remarkable new obesity drugs. Both of them have potential to bring important advances. Both of them need more work before they will be ready to go to FDA for approval. This was a rare treat. Bimagrumab The […]
June 23, 2025 — With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]
June 21, 2025 — “It takes a village to create standards of care,” said Nuha Ali El Sayed as she opened a symposium on the emerging standards of care for obesity. Truer words were never spoken. Defining these standards is tricky. That’s because they they need to reflect both what is desirable and a standard that good health professionals […]
June 20, 2025 — We are landing in Chicago for the ADA Scientific Sessions and you can be sure that a veritable river of news about obesity will be flowing. Everything from basic science to innovative treatment and pragmatic approaches for clinical care and policy will be offered up by this meeting of the American Diabetes Association. This promises […]
June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]
June 24, 2024 — One thing is plain to us in the huge showing of interest in obesity at the American Diabetes Association Scientific Sessions (ADA2024). The scale of opportunity is large because the unmet medical need is great. And yet we face a tremendous problem of scale for coping with the need for obesity care. We have problems […]
June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]
June 26, 2023 — “We may be on the cusp of an era of astonishing innovation – the limits of which aren’t even clear yet,” writes David Wallace-Wells in the New York Times. Among other breakthroughs, he cites the transformation in care that semaglutide and tirzepatide are bringing for the most prevalent chronic disease in the world – obesity. […]
June 25, 2023 — We take it as a given – we want to eat healthy. Since 2016, FDA has been working on developing an updated definition for the meaning of “healthy” if a food seller wants to say that about one of its products. The agency is still struggling with this question today. So we were glad to […]
